APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027

Abstract
The Asia Pacific in situ hybridization market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.

“The kits & reagents segment accounted for the highest share in the Asia Pacific ISH consumables market revenue for the year 2021”

The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.

“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”

Based on the end users the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.
 
“China: The fastest-growing country in the Asia Pacific in situ hybridization market”

The Asia Pacific in situ hybridization market is segmented into Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific. China market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the country, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the country.

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side 20%
•By Designation: C-level - 25%, D-level - 20%, and Others - 55%

Lists of Companies Profiled in the Report:
•Abbott (US)
•Abbott Laboratories (US)
•Thermo Fisher Scientific (US)
•Danaher Corporation (US)
•Merck (Germany)
•F. Hoffmann-La Roche (Switzerland)
•BioView (Israel)
•Agilent Technologies (US)
•Biocare Medical (US)
•Bio-Techne Corporation (US)
•QIAGEN (Germany)
•PerkinElmer (US)
•Enzo Biochem (US)
•Bio-Rad Laboratories (US)
•Abnova Corporation (Taiwan)
•BioGenex Laboratories (US)
•OpGen (US)
•Bio SB (US)
•Abcam (UK)
•Zytomed (Germany)
•10x Genomics Inc. (US)
•NeoGenomics Laboratories (US).

Research Coverage:
This report provides a detailed picture of the Asia Pacific in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and country. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Content
Table of Contents

1INTRODUCTION22
1.1STUDY OBJECTIVES22
1.2MARKET DEFINITION22
1.2.1INCLUSIONS & EXCLUSIONS22
1.3MARKET SCOPE23
1.3.1MARKETS COVERED23
1.4YEARS CONSIDERED23
1.5CURRENCY CONSIDERED24
1.6LIMITATIONS24
1.7STAKEHOLDERS24
1.8SUMMARY OF CHANGES24
2RESEARCH METHODOLOGY25
2.1RESEARCH DATA25
FIGURE 1RESEARCH DESIGN25
2.1.1SECONDARY DATA25
2.1.2PRIMARY DATA26
FIGURE 2BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET26
2.2MARKET ESTIMATION METHODOLOGY27
FIGURE 3MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)27
FIGURE 4APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION)27
FIGURE 5APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022−2027)28
FIGURE 6APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES28
2.3MARKET DATA ESTIMATION & TRIANGULATION29
FIGURE 7DATA TRIANGULATION METHODOLOGY29
2.4INDUSTRY INSIGHTS30
2.5RESEARCH ASSUMPTIONS30
3EXECUTIVE SUMMARY31
FIGURE 8APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)31
FIGURE 9APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 202131
FIGURE 10APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)32
FIGURE 11APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 202132
FIGURE 12APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)33
4PREMIUM INSIGHTS34
4.1APAC IN SITU HYBRIDIZATION MARKET OVERVIEW34
FIGURE 13GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH34
4.2APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)35
FIGURE 14HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD35
5MARKET OVERVIEW36
5.1INTRODUCTION36
5.2MARKET DYNAMICS36
FIGURE 15APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES36
TABLE 1APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS37
5.2.1DRIVERS37
5.2.1.1Increasing incidence of genetic disorders and cancer37
TABLE 2NEW CASES OF CANCER IN ASIA, 2020 VS. 202537
FIGURE 16HEMOPHILIA OCCURRENCE, BY REGION38
5.2.1.2Growing awareness about companion diagnostics38
5.2.2OPPORTUNITIES38
5.2.2.1Untapped markets in developing countries38
5.2.3CHALLENGES39
5.2.3.1Shortage of skilled professionals39
5.3PORTER’S FIVE FORCES ANALYSIS39
TABLE 3APAC IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS39
5.3.1THREAT FROM NEW ENTRANTS39
5.3.2THREAT FROM SUBSTITUTES39
5.3.3BARGAINING POWER OF BUYERS40
5.3.4BARGAINING POWER OF SUPPLIERS40
5.3.5INTENSITY OF COMPETITIVE RIVALRY40
5.4SUPPLY CHAIN ANALYSIS40
FIGURE 17SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET41
5.5VALUE CHAIN ANALYSIS42
FIGURE 18VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET42
5.6ECOSYSTEM ANALYSIS43
FIGURE 19ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET43
5.7KEY CONFERENCES & EVENTS IN 2022–202343
TABLE 4KEY CONFERENCES & EVENTS, 2022–202343
5.8REGULATORY ANALYSIS44
5.8.1FDA APPROVALS44
5.8.2REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS44
TABLE 5ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS44
5.9PRICING ANALYSIS45
TABLE 6PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS45
5.9.1APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS45
TABLE 7PRICING ANALYSIS OF FISH TESTS IN INDIA (2021)46
5.10KEY STAKEHOLDERS AND BUYING CRITERIA47
5.10.1KEY STAKEHOLDERS IN BUYING PROCESS47
FIGURE 20INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC47
5.10.2BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC48
FIGURE 21KEY BUYING CRITERIA FOR END USERS48
6APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT49
6.1INTRODUCTION50
TABLE 8APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)50
6.2CONSUMABLES50
TABLE 9APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)50
TABLE 10APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)51
6.2.1PROBES51
6.2.1.1Growing preference for direct localization of DNA/RNA sequences using probes to drive market51
TABLE 11APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)51
6.2.2KITS & REAGENTS52
6.2.2.1Growing focus on companion diagnostics to boost demand52
TABLE 12APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)52
6.2.3ACCESSORIES52
6.2.3.1Use of accessories for optimal performance of FISH and CISH probes to propel adoption52
TABLE 13APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)53
6.3INSTRUMENTS53
6.3.1RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET53
TABLE 14APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)54
6.4SOFTWARE54
6.4.1GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET54
TABLE 15APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)55
7APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION56
7.1INTRODUCTION57
TABLE 16APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)57
7.2CANCER DIAGNOSTICS57
7.2.1GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET57
TABLE 17APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)58
7.3CYTOLOGY58
7.3.1GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET58
TABLE 18APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)59
7.4INFECTIOUS DISEASE DIAGNOSTICS59
7.4.1NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH59
TABLE 19APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)60
7.5NEUROSCIENCE60
7.5.1RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES60
TABLE 20APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)61
7.6IMMUNOLOGY61
7.6.1RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH61
TABLE 21APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)62
8APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY63
8.1INTRODUCTION64
TABLE 22APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)64
8.2FLUORESCENCE IN SITU HYBRIDIZATION (FISH)64
TABLE 23APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)64
TABLE 24APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)65
8.2.1DNA FLUORESCENCE IN SITU HYBRIDIZATION65
8.2.1.1Need to ensure stability of genetic material to drive market65
TABLE 25APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)66
8.2.2RNA FLUORESCENCE IN SITU HYBRIDIZATION66
8.2.2.1Increasing biomedical research to support market growth66
TABLE 26APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)67
8.2.3PNA FLUORESCENCE IN SITU HYBRIDIZATION67
8.2.3.1Increased applications in infectious disease diagnosis to boost market67
TABLE 27APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)68
8.3CHROMOGENIC IN SITU HYBRIDIZATION (CISH)68
8.3.1COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH68
TABLE 28APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)69
9APAC IN SITU HYBRIDIZATION MARKET, BY END USER70
9.1INTRODUCTION71
TABLE 29APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)71
9.2HOSPITAL & DIAGNOSTIC LABORATORIES71
9.2.1GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET71
TABLE 30APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)72
9.3ACADEMIC & RESEARCH INSTITUTES72
9.3.1GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET72
TABLE 31APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)73
9.4PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES73
9.4.1NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH73
TABLE 32APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)74
9.5CONTRACT RESEARCH ORGANIZATIONS74
9.5.1INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET74
TABLE 33APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)75
10APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY76
10.1INTRODUCTION77
FIGURE 22APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT77
TABLE 34APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)78
10.1.1JAPAN78
10.1.1.1Growing focus on personalized diagnostics to support market growth78
TABLE 35JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)79
TABLE 36JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)79
TABLE 37JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)79
TABLE 38JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)80
TABLE 39JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)80
TABLE 40JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)80
10.1.2CHINA81
10.1.2.1China to register highest CAGR during forecast period81
TABLE 41CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)81
TABLE 42CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)81
TABLE 43CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)82
TABLE 44CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)82
TABLE 45CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)82
TABLE 46CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)83
10.1.3INDIA83
10.1.3.1Collaborations between hospitals and diagnostic labs to propel market growth in India83
TABLE 47INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)83
TABLE 48INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)84
TABLE 49INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)84
TABLE 50INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)84
TABLE 51INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)85
TABLE 52INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)85
10.1.4SOUTH KOREA85
10.1.4.1Robust healthcare infrastructure to boost growth85
TABLE 53SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)86
TABLE 54SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)86
TABLE 55SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)86
TABLE 56SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)87
TABLE 57SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)87
TABLE 58SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)87
10.1.5TAIWAN88
10.1.5.1Improving cancer research and care to propel demand for ISH88
TABLE 59TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)88
TABLE 60TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)88
TABLE 61TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)89
TABLE 62TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)89
TABLE 63TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)89
TABLE 64TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)90
10.1.6SINGAPORE90
10.1.6.1Government initiatives to make cancer treatment more affordable to contribute to growth90
TABLE 65SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)90
TABLE 66SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)91
TABLE 67SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)91
TABLE 68SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)91
TABLE 69SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)92
TABLE 70SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)92
10.1.7AUSTRALIA93
10.1.7.1Increasing public-private investments in cancer research to boost demand93
TABLE 71AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)93
TABLE 72AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)94
TABLE 73AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)94
TABLE 74AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)94
TABLE 75AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)95
TABLE 76AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)95
10.1.8NEW ZEALAND95
10.1.8.1Rising cases of cancer to propel growth95
TABLE 77NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)96
TABLE 78NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)96
TABLE 79NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)96
TABLE 80NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)97
TABLE 81NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)97
TABLE 82NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)97
10.1.9REST OF ASIA PACIFIC98
TABLE 83REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)98
TABLE 84REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)98
TABLE 85REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)99
TABLE 86REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)99
TABLE 87REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)99
TABLE 88REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)100
11COMPETITIVE LANDSCAPE101
11.1INTRODUCTION101
11.2RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS101
TABLE 89APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS101
11.3MARKET SHARE ANALYSIS102
FIGURE 23APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021)102
11.4REVENUE SHARE ANALYSIS103
FIGURE 24REVENUE ANALYSIS OF KEY COMPANIES (2019−2021)103
11.5COMPANY EVALUATION QUADRANT104
11.5.1STARS104
11.5.2EMERGING LEADERS104
11.5.3PERVASIVE PLAYERS104
11.5.4PARTICIPANTS104
FIGURE 25APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)105
11.6COMPETITIVE SCENARIO AND TRENDS106
11.6.1PRODUCT LAUNCHES106
TABLE 90APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019–2022106
11.6.2DEALS107
TABLE 91APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019–2022107
 
12COMPANY PROFILES108
12.1KEY COMPANIES108
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1ABBOTT LABORATORIES108
TABLE 92ABBOTT LABORATORIES: BUSINESS OVERVIEW108
FIGURE 26ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)109
12.1.2F. HOFFMANN-LA ROCHE AG111
TABLE 93F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW111
FIGURE 27F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)112
12.1.3THERMO FISHER SCIENTIFIC, INC.114
TABLE 94THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW114
FIGURE 28THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)115
12.1.4DANAHER CORPORATION117
TABLE 95DANAHER CORPORATION: BUSINESS OVERVIEW117
FIGURE 29DANAHER CORPORATION: COMPANY SNAPSHOT (2021)118
12.1.5AGILENT TECHNOLOGIES, INC.120
TABLE 96AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW120
FIGURE 30AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)121
12.1.6BIOCARE MEDICAL123
TABLE 97BIOCARE MEDICAL: BUSINESS OVERVIEW123
12.1.7BIO-TECHNE CORPORATION125
TABLE 98BIO-TECHNE CORPORATION: BUSINESS OVERVIEW125
FIGURE 31BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)126
12.1.8QIAGEN N.V.128
TABLE 99QIAGEN N.V.: BUSINESS OVERVIEW128
FIGURE 32QIAGEN N.V.: COMPANY SNAPSHOT (2021)129
12.1.9MERCK KGAA130
TABLE 100MERCK KGAA: BUSINESS OVERVIEW130
FIGURE 33MERCK KGAA: COMPANY SNAPSHOT (2021)131
12.1.10PERKINELMER132
TABLE 101PERKINELMER: BUSINESS OVERVIEW132
FIGURE 34PERKINELMER: COMPANY SNAPSHOT (2021)133
12.1.11ENZO BIOCHEM134
TABLE 102ENZO BIOCHEM: BUSINESS OVERVIEW134
FIGURE 35ENZO BIOCHEM: COMPANY SNAPSHOT (2021)135
12.1.12BIO-RAD LABORATORIES137
TABLE 103BIO-RAD LABORATORIES: BUSINESS OVERVIEW137
FIGURE 36BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)138
12.1.13ABNOVA CORPORATION139
TABLE 104ABNOVA CORPORATION: BUSINESS OVERVIEW139
12.1.14BIOGENEX LABORATORIES140
TABLE 105BIOGENEX LABORATORIES: BUSINESS OVERVIEW140
12.1.15OPGEN INC.142
TABLE 106OPGEN INC.: BUSINESS OVERVIEW142
FIGURE 37OPGEN INC.: COMPANY SNAPSHOT (2021)143
12.1.16BIO SB144
TABLE 107BIO SB: BUSINESS OVERVIEW144
12.1.17ABCAM145
TABLE 108ABCAM: BUSINESS OVERVIEW145
FIGURE 38ABCAM: COMPANY SNAPSHOT (2021)145
12.1.18ZYTOMED SYSTEMS GMBH147
TABLE 109ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW147
12.1.19NEOGENOMICS LABORATORIES148
TABLE 110NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW148
FIGURE 39NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021)148
12.1.20BIOVIEW150
TABLE 111BIOVIEW: BUSINESS OVERVIEW150
FIGURE 40BIOVIEW: COMPANY SNAPSHOT (2021)150
12.1.2110X GENOMICS151
TABLE 11210X GENOMICS: BUSINESS OVERVIEW151
FIGURE 4110X GENOMICS: COMPANY SNAPSHOT (2021)151
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13APPENDIX153
13.1DISCUSSION GUIDE153
13.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL155
13.3CUSTOMIZATION OPTIONS157
13.4RELATED REPORTS157
13.5AUTHOR DETAILS158